Among ultra-high-priced drugs with an annual drug cost of more than 10 million won per patient, RSA contract drugs have increased significantly. It was confirmed that the claims for RSA drugs increased by an average of 62.6% per year. This fact was found in the "Research on the Performance Evaluation and Development Direction of RSA" conducted by the Industrial-Academic Cooperation Group of Seoul National University (Professor Lee Tae-jin), at the request of the NHIS. The results of this study were partially released on the 2nd through the management information disclosure system (Alio) of public institutions. The research team surveyed the cost of claiming risk-sharing drugs among high-priced drugs exceeding 10 million